These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38753754)

  • 1. Molecular Imaging and Therapy of Differentiated Thyroid Carcinoma in Adults.
    Mulugeta PG; Chi AW; Anderson TM
    Cancer J; 2024 May-Jun 01; 30(3):194-201. PubMed ID: 38753754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.
    Liu J; Liu Y; Lin Y; Liang J
    Endocrinol Metab (Seoul); 2019 Sep; 34(3):215-225. PubMed ID: 31565873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-translational Regulation of Radioactive Iodine Therapy Response in Papillary Thyroid Carcinoma.
    Amit M; Na'ara S; Francis D; Matanis W; Zolotov S; Eisenhaber B; Eisenhaber F; Weiler Sagie M; Malkin L; Billan S; Charas T; Gil Z
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 30053080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
    Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NIS and epithelial-mesenchymal transition marker expression of circulating tumor cells for predicting and monitoring the radioactive iodine-131 therapy effect in differentiated thyroid cancers.
    Zheng L; Wang G; Guo W; Pan D; Xie L; He S; Luo C; Li H; Ran Y; Wu S; Liu F; Zhang X; Huang D
    Mol Biol Rep; 2019 Aug; 46(4):4201-4212. PubMed ID: 31147861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer.
    Cai X; Wang R; Tan J; Meng Z; Li N
    Clin Transl Oncol; 2021 Dec; 23(12):2403-2414. PubMed ID: 34100218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.
    Oh JM; Ahn BC
    Theranostics; 2021; 11(13):6251-6277. PubMed ID: 33995657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond.
    Santhanam P; Solnes LB; Rowe SP
    Med Oncol; 2017 Oct; 34(12):189. PubMed ID: 29086115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
    Oh JM; Baek SH; Gangadaran P; Hong CM; Rajendran RL; Lee HW; Zhu L; Gopal A; Kalimuthu S; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2020 Apr; 30(4):501-518. PubMed ID: 31928162
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of Patient Age and Histological Type on Radioactive Iodine Avidity of Recurrent Lesions of Differentiated Thyroid Carcinoma.
    Nakanishi K; Kikumori T; Miyajima N; Takano Y; Noda S; Takeuchi D; Iwano S; Kodera Y
    Clin Nucl Med; 2018 Jul; 43(7):482-485. PubMed ID: 29688947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
    Reddi HV; Madde P; McDonough SJ; Trujillo MA; Morris JC; Myers RM; Peng KW; Russell SJ; McIver B; Eberhardt NL
    Cancer Gene Ther; 2012 Sep; 19(9):659-65. PubMed ID: 22790962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Combination Therapy with Lenvatinib and Radioactive Iodine in Thyroid Cancer Preclinical Model.
    Suzuki K; Iwai H; Utsunomiya K; Kono Y; Watabe T; Kobayashi Y; Bui DV; Sawada S; Yun Y; Mitani A; Fukui K; Sakai H; Chu HH; Linh NM; Tanigawa N; Kanda A
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reinforcing the Ability of 99mTcO4 Scintigraphy for Identifying Differentiated Thyroid Cancer by TSH Stimulation.
    Ahn BC
    Clin Nucl Med; 2016 Sep; 41(9):e412-3. PubMed ID: 27405037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical approach and radioactive iodine therapy for small well-differentiated thyroid cancer.
    Momesso DP; Vaisman F; Caminha LS; Pessoa CH; Corbo R; Vaisman M
    J Endocrinol Invest; 2014 Jan; 37(1):57-64. PubMed ID: 24464451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of Na+/I- symporter in thyroid cancers in an iodine-deficient population: an immunohistochemical study.
    Mishra A; Pal L; Mishra SK
    World J Surg; 2007 Sep; 31(9):1737-1742. PubMed ID: 17653791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

  • 18. Predictive role of nontumoral sodium iodide symporter activity and preoperative thyroid characteristics in remission process of thyroid cancer patients.
    Yildirim-Poyraz N; Yazgan A; Ozdemir E; Gozalan A; Keskin M; Ersoy R; Turkolmez S; Cakir B
    Ann Nucl Med; 2014 Aug; 28(7):623-31. PubMed ID: 24823701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent disease in juvenile differentiated thyroid carcinoma: prognostic factors, treatments, and outcomes.
    Mihailovic J; Nikoletic K; Srbovan D
    J Nucl Med; 2014 May; 55(5):710-7. PubMed ID: 24722527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer.
    Plantinga TS; Tesselaar MH; Morreau H; Corssmit EP; Willemsen BK; Kusters B; van Engen-van Grunsven AC; Smit JW; Netea-Maier RT
    Autophagy; 2016 Jul; 12(7):1195-205. PubMed ID: 27105307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.